Alkem Laboratories hosted its Q1 FY27 earnings call, reporting 11% YoY revenue growth to INR3,740 crore and a 21.7% net profit decline due to tax effects.
The company's India business grew 10.3%, outperforming the IPM by 100 bps, while its Daman facility received an OAI status from the US FDA.
Management provided updates on its CDMO and MedTech ventures, noting a quarterly EBITDA loss of INR5-7 crores for MedTech and INR60 crores in opex for the US CDMO business.
Guidance was reaffirmed, expecting high single-digit US growth, ~12% India growth, and consolidated gross margins of 66.5-67% for FY27.